In an attempt to regain its boom in the market, Amgen Inc. has planned to launch its recently approved drug Prolia next week at a high price. Its two injections yearly will cost $1,650. The drug is capable of reducing the risk of bone collapsing or fracture risk in women with osteoporosis after menopause.

Meanwhile, the American Society of Clinical Oncology researchers will be presenting a report on the effectiveness of a drug called denosumab in delaying the fractures and preventing the complications associated with prostate cancer, which hits the bones.

If Amgen wins FDA's approval for its new drug for cancer patients, its sales are likely to cross the $3 billion by the middle of the nest decade, said analysts.

Amgen's total revenue for 2009 was reported to be $14.6 billion.

However, Prolia's sales are not expected to rise much initially. For its use in osteoporosis, Amgen will have to establish traction among doctors who treat the eight million women suffering from bone collapses in the U. S.

"It's a very effective drug. They've priced it at the upper end of competitors," said Sundeep Khosla, an endocrinologist and osteoporosis expert at Mayo Clinic, Rochester, Minn.